Assessment of Primary Colorectal Cancer Heterogeneity by Using Whole-Tumor Texture Analysis: Contrast-enhanced CT Texture as a Biomarker of 5-year Survival

Published Online:https://doi.org/10.1148/radiol.12120254

Fine-texture features (lower entropy, kurtosis, and standard deviation; higher uniformity and skewness) were associated with a poorer 5-year overall survival rate in patients with colorectal cancer.

Purpose

To determine if computed tomographic (CT) texture features of primary colorectal cancer are related to 5-year overall survival rate.

Materials and Methods

Institutional review board waiver was obtained for this retrospective analysis. Texture features of the entire primary tumor were assessed with contrast material–enhanced staging CT studies obtained in 57 patients as part of an ethically approved study and by using proprietary software. Entropy, uniformity, kurtosis, skewness, and standard deviation of the pixel distribution histogram were derived from CT images without filtration and with filter values corresponding to fine (1.0), medium (1.5, 2.0), and coarse (2.5) textures. Patients were followed up until death and were censored at 5 years if they were still alive. Kaplan-Meier analysis was performed to determine the relationship, if any, between CT texture and 5-year overall survival rate. The Cox proportional hazards model was used to assess independence of texture parameters from stage.

Results

Follow-up data were available for 55 of 57 patients. There were eight stage I, 19 stage II, 17 stage III, and 11 stage IV cancers. Fine-texture feature Kaplan-Meier survival plots for entropy, uniformity, kurtosis, skewness, and standard deviation of the pixel distribution histogram were significantly different for tumors above and below each respective threshold receiver operating characteristic (ROC) curve optimal cutoff value (P = .001, P = .018, P = .032, P = .008, and P = .001, respectively), with poorer prognosis for ROC optimal values (a) less than 7.89 for entropy, (b) at least 0.01 for uniformity, (c) less than 2.48 for kurtosis, (d) at least −0.38 for skewness, and (e) less than 61.83 for standard deviation. Multivariate Cox proportional hazards regression analysis showed that each parameter was independent from the stage predictor of overall survival rate (P = .001, P = .009, P = .006, P = .02, and P = .001, respectively).

Conclusion

Fine-texture features are associated with poorer 5-year overall survival rate in patients with primary colorectal cancer.

© RSNA, 2012

Supplemental material:

References

  • 1 Sargent D, Shi Q, Yothers G, et al.. Two or three year disease-free survival (DFS) as a primary end-point in stage III adjuvant colon cancer trials with fluoropyrimidines with or without oxaliplatin or irinotecan: data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer 2011;47(7):990–996. Crossref, MedlineGoogle Scholar
  • 2 McArdle CS, Hole D, Hansell D, Blumgart LH, Wood CB. Prospective study of colorectal cancer in the west of Scotland: 10-year follow-up. Br J Surg 1990;77(3):280–282. Crossref, MedlineGoogle Scholar
  • 3 Sargent DJ, Wieand HS, Haller DG, et al.. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005;23(34):8664–8670. Crossref, MedlineGoogle Scholar
  • 4 Sargent DJ, Patiyil S, Yothers G, et al.. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group. J Clin Oncol 2007;25(29):4569–4574. Crossref, MedlineGoogle Scholar
  • 5 Scheele J, Stangl R, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg 1990;77(11):1241–1246. Crossref, MedlineGoogle Scholar
  • 6 Desch CE, Benson AB, Somerfield MR, et al.. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2005;23(33):8512–8519. Crossref, MedlineGoogle Scholar
  • 7 Nelson DA, Tan TT, Rabson AB, Anderson D, Degenhardt K, White E. Hypoxia and defective apoptosis drive genomic instability and tumorigenesis. Genes Dev 2004;18(17):2095–2107. Crossref, MedlineGoogle Scholar
  • 8 Ganeshan B, Miles KA, Young RC, Chatwin CR. Hepatic enhancement in colorectal cancer: texture analysis correlates with hepatic hemodynamics and patient survival. Acad Radiol 2007;14(12):1520–1530. Crossref, MedlineGoogle Scholar
  • 9 Miles KA, Ganeshan B, Griffiths MR, Young RC, Chatwin CR. Colorectal cancer: texture analysis of portal phase hepatic CT images as a potential marker of survival. Radiology 2009;250(2):444–452. LinkGoogle Scholar
  • 10 Goh V, Halligan S, Wellsted DM, Bartram CI. Can perfusion CT assessment of primary colorectal adenocarcinoma blood flow at staging predict for subsequent metastatic disease? a pilot study. Eur Radiol 2009;19(1):79–89. Crossref, MedlineGoogle Scholar
  • 11 Greene FLPage DLFleming IDet al. (eds). AJCC Cancer Staging Manual. 6th ed. Heidelberg, Germany: Springer-Verlag, 2002. CrossrefGoogle Scholar
  • 12 Semenza GL. HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol Med 2002;8(4 Suppl):S62–S67. Crossref, MedlineGoogle Scholar
  • 13 Lunt SJ, Chaudary N, Hill RP. The tumor microenvironment and metastatic disease. Clin Exp Metastasis 2009;26(1):19–34. Crossref, MedlineGoogle Scholar
  • 14 Cui C, Cai H, Liu L, Li L, Tian H, Li L. Quantitative analysis and prediction of regional lymph node status in rectal cancer based on computed tomography imaging. Eur Radiol 2011;21(11):2318–2325. Crossref, MedlineGoogle Scholar
  • 15 Ganeshan B, Skogen K, Pressney I, Coutroubis D, Miles K. Tumour heterogeneity in oesophageal cancer assessed by CT texture analysis: preliminary evidence of an association with tumour metabolism, stage, and survival. Clin Radiol 2012;67(2):157–164. Crossref, MedlineGoogle Scholar
  • 16 Ganeshan B, Abaleke S, Young RC, Chatwin CR, Miles KA. Texture analysis of non-small cell lung cancer on unenhanced computed tomography: initial evidence for a relationship with tumour glucose metabolism and stage. Cancer Imaging 2010;10:137–143. Crossref, MedlineGoogle Scholar
  • 17 Ganeshan B, Miles KA, Young RC, Chatwin CR. Texture analysis in non-contrast enhanced CT: impact of malignancy on texture in apparently disease-free areas of the liver. Eur J Radiol 2009;70(1):101–110. Crossref, MedlineGoogle Scholar
  • 18 Ganeshan B, Burnand K, Young R, Chatwin C, Miles K. Dynamic contrast-enhanced texture analysis of the liver: initial assessment in colorectal cancer. Invest Radiol 2011;46(3):160–168. Crossref, MedlineGoogle Scholar
  • 19 Bézy-Wendling J, Kretowski M, Rolland Y, Le Bidon W. Toward a better understanding of texture in vascular CT scan simulated images. IEEE Trans Biomed Eng 2001;48(1):120–124. Crossref, MedlineGoogle Scholar
  • 20 Yonenaga Y, Mori A, Onodera H, et al.. Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients. Oncology 2005;69(2):159–166. Crossref, MedlineGoogle Scholar
  • 21 Goh V, Ganeshan B, Nathan P, Juttla JK, Vinayan A, Miles KA. Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. Radiology 2011;261(1):165–171. LinkGoogle Scholar

Article History

Received January 31, 2012; revision requested March 23; revision received May 1; accepted May 17; final version accepted July 17.
Published online: Jan 2013
Published in print: Jan 2013